Alterity Therapeutics is proceeding with its Phase II trial of ATH434 in Multiple System Atrophy (MSA) after it received acceptance from the UK Medicines & Healthcare products Regulatory Agency (MHRA) of its clinical trial authorization (CTA) request.

The randomised, double-blind, placebo-controlled study will analyse the company’s lead candidate, ATH434, in patients with early-stage MSA, a rare, neurodegenerative disease.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The study will explore the candidate’s treatment effect on imaging and protein biomarkers such as aggregating α-synuclein and excess iron, the key contributors to MSA pathology.

Clinical endpoints and other biomarkers will enable assessment of the therapy’s efficacy, along with safety and pharmacokinetics’ characterisation.

In this trial, subjects will be given treatment for 12 months, which will help detect changes in efficacy endpoints.

See Also:

This will enable to optimise design of a definitive Phase III clinical trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Alterity Therapeutics CEO David Stamler said: “Approval by the MHRA in the UK is another important step forward for our ATH434 clinical development programme.

“We expect to open our first Phase II clinical trial site in New Zealand this quarter and then expand the trial globally in the UK, other European countries, Australia and the United States.

“We look forward to bringing this potential therapy to individuals with MSA who currently have no treatments to address the underlying pathology of their disease.”

ATH434, which has been designed to prevent aggregation of pathological proteins implicated in neurodegeneration, received Orphan designation from the US Food and Drug Administration and the European Commission to treat MSA.

Autonomic nervous system failure and impaired movement cause MSA and its symptoms reflect the progressive loss of function and various nerve cells death in the brain and spinal cord.